1. Questions or comments on this presentation can be addressed to alastair.buxton@psnc.org.uk alastair.buxton@psnc.org.uk You can pick and choose the elements of the presentation that suit the needs of your event / discussion with GP practice colleagues Documents summarising the Advanced services for GP practices and describing the work of community pharmacies can be found at http://psnc.org.uk/services-commissioning/working-with-gps/ Last updated: 28 th August 2013 Read and delete this slide…

2. The NHS New Medicine Service and targeted MURs NHS Community Pharmacy Contractual Framework

3. Estimates vary on the frequency of non-adherence: – Between 33% and 50% of medicines for LTCs are not used as recommended – 20-30% don’t adhere to regimens that are curative or relieve symptoms – 30-40% fail to follow regimens designed to prevent health problems It has been suggested that increasing the effectiveness of adherence interventions may have a far greater impact on the health of the population than any improvement in specific medical treatments Haynes R, McDonald H, Garg A, Montague P. (2002). Interventions for helping patients to follow prescriptions for medications. The Cochrane Database of Systematic Reviews, 2, CD000011. The challenge of non-adherence

4. Research published in 2004 showed that 10 days after starting a new medicine: – 7% of patients had completely stopped taking the medicine (completely non- adherent) – 30% of patients still taking the medicine were non-adherent – 45% of non-adherence was intentional (the remainder was unintentional) – 61% of patients expressed a substantial and sustained need for further information – 66% of patients still taking their medicine reported at least one problem with it: Side effects (50%) Concerns about the medication (43%) Difficulties with the practical aspects of taking the medication (7%) Patients’ problems with new medication for chronic conditions. Barber N et al. Qual Saf Health Care 2004;13:172-175 Non-adherence to newly prescribed medicines

5. Research was published in 2006 reporting on a randomised controlled trial (n=500) on which the NMS is based At 4-week follow-up, non-adherence was significantly lower in the intervention group compared to control (9% versus 16%, P = 0.032) The number of patients reporting medicine-related problems was significantly lower in the intervention group compared to the control (23% vs. 34%, P = 0.021) Intervention group patients also had more positive beliefs about their new medicine, as shown by their higher score on the ‘‘necessity-concerns differential’’ (5.0 vs. 3.5, P = 0.007) Patient-centred advice is effective in improving adherence to medicines. Clifford S et al. Pharm World Sci 2006;28:165-170 The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. Elliott R A et al. Pharm World Sci 2008;30:17-23 The ‘NMS’ research

6. Provides early support to patients to maximise the benefits of prescribed medication Proof of concept research shows that an intervention by a pharmacist can help to improve patients’ adherence In the research patients who used the service experienced fewer medicines problems and made less use of other NHS services, saving money and GP time The cost of the service is offset by savings created by community pharmacy medicines procurement New Medicine Service

7. PSNC and NHS Employers envisage that the successful implementation of NMS will: – improve patient adherence – increase patient engagement with their condition and medicines – reduce medicines wastage – reduce hospital admissions due to adverse events from medicines – lead to increased Yellow Card reporting – receive positive assessment from patients – support the development of outcome and/or quality measures for community pharmacy Potential benefits

8. Three stage process 1.Patient engagement (day 0) 2.Intervention (approx. day 14) 3.Follow up (approx. day 28) Opportunity to provide healthy living advice at each stage NMS – outline service spec

9. Follows the prescribing of a new medicine for: ₋Asthma or COPD ₋Diabetes (Type 2) ₋Antiplatelet / Anticoagulant therapy ₋Hypertension Recruitment by pharmacy or via referral NMS – Patient engagement

10. Intervention typically day 7 – 14 – Face to face in a consultation area or over the phone – Semi-structured interview technique to: assess adherence identify problems identify the patient’s need for further information and support – Pharmacist provides advice and support agrees follow up agrees solution(s) refers to GP (only where absolutely necessary) NMS – Intervention

11. Follow up typically between 14 and 21 days after the Intervention – Face to face in a consultation area or over the phone – Semi-structured interview technique to: assess adherence identify problems identify the patient’s need for further information and support – Pharmacist provides advice and support Patient adherent Patient non-adherent provide more advice and support or refer to GP (using nationally agreed NMS Feedback form) NMS – Follow up

12. Pharmacies must have a consultation area that meets the requirements for the MUR service in order to provide the NMS Premises requirements

13. Pharmacy contractors or their representative must communicate with local GP Practices before providing NMS A briefing document for GP Practice teams is available from the PSNC website Communicating with GP practices

14. National NMS Feedback Form designed by GPC/PSNC/NHS Employers Referrals will only be made when absolutely necessary GPC advised that pharmacists should refer to the practice, rather than suggesting patients make an appointment with their GP This approach allows the practice to determine how they want to deal with the issue raised in the Feedback Form Referring to the GP practice

15. GPs will also only be sent forms if an issue is identified that the GP needs to address, Dr Bill Beeby, chairman of the GPC clinical and prescribing committee, told GPonline.com. He said the final version of the form would be easy for GPs to gain information from and would improve patient safety. ‘The form will be on one side of paper,’ he said. ‘GPs won’t be inundated with non-reports.’ Reports would only be sent when the pharmacist identified an issue with a patient initiated on a medicine that the GP needed to deal with, he said. ‘For the vast majority you won’t get a piece of paper.’ http://www.gponline.com/News/article/1083644/GPs- wont-inundated-new-pharmacy-report-forms/ Referring to the GP practice

16. Laurence Buckman, Former Chairman of the GPC “If both professions can form stronger links it will benefit both them and their patients. LMCs and LPCs are ideally placed to make this happen.” The BMA viewpoint

17. Dr Clare Gerada, Former Chair of the Royal College of General Practitioners “Patients do sometimes experience problems with their medicines and, through the New Medicine Service, GPs and pharmacists will work in partnership to ensure those that need support receive it. This will result in improving the care we provide to our patients, and in turn our patients’ health.” The RCGP viewpoint

18. MURs aim to improve a patient’s knowledge, understanding and use of their medicines From 1 October 2011 pharmacies must ensure that at least 50% of the MURs they provide are targeted on patients who: – are taking “high risk medicines” (diuretics, NSAIDs, antiplatelets and anticoagulants) – have been recently discharged from hospital with an amended medicines regimen. Ideally patients who are discharged from hospital will receive an MUR within four weeks of discharge but in certain circumstances the MUR can take place within eight weeks of discharge – have respiratory disease Targeted MURs

19. MURs cover all the patient’s medicines not just those that fall within a target group Pharmacists will still be able to provide MURs to patients who fall outside of the target groups who they think would benefit from the intervention Targeted MURs

20. Questions, comments and next steps Working together…